These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 19953518)

  • 21. [Discontinuation of treatment with platelet aggregation inhibitors in surgical patients with cardiac stents].
    Johansen M; Afshari A; Kristensen BB
    Ugeskr Laeger; 2010 Mar; 172(11):852-7. PubMed ID: 20403266
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dose-related effect of aspirin on laboratory-defined platelet aggregation and clinical outcome after coronary stenting.
    Kojuri J; Mahmoody Y; Zangbar Sabegh B; Jannati M; Mahboodi A; Khalili A
    Cardiovasc Ther; 2010 Jun; 28(3):147-52. PubMed ID: 20557313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Triple therapy: triple safety or triple danger?
    Dewilde W; Breet N; Ten Berg J
    Am J Cardiol; 2010 Feb; 105(4):579. PubMed ID: 20152257
    [No Abstract]   [Full Text] [Related]  

  • 24. Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention.
    Brener SJ; Moliterno DJ; Lincoff AM; Steinhubl SR; Wolski KE; Topol EJ
    Circulation; 2004 Aug; 110(8):994-8. PubMed ID: 15302778
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.
    Mehilli J; Kastrati A; Schühlen H; Dibra A; Dotzer F; von Beckerath N; Bollwein H; Pache J; Dirschinger J; Berger PP; Schömig A;
    Circulation; 2004 Dec; 110(24):3627-35. PubMed ID: 15531766
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial.
    Collet JP; Montalescot G; Steg PG; Steinhubl SR; Fox KA; Hu TF; Johnston SC; Hamm CW; Bhatt DL; Topol EJ
    Arch Cardiovasc Dis; 2009; 102(6-7):485-96. PubMed ID: 19664568
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug-eluting stents: safe but not sufficient.
    Vogel RA
    JACC Cardiovasc Interv; 2009 Jun; 2(6):513-4. PubMed ID: 19539254
    [No Abstract]   [Full Text] [Related]  

  • 28. Acknowledging a failed strategy.
    Bass TA
    Catheter Cardiovasc Interv; 2009 Jun; 73(7):871-3. PubMed ID: 19455650
    [No Abstract]   [Full Text] [Related]  

  • 29. Glycoprotein IIb/IIIa receptor inhibition with abciximab during percutaneous coronary interventions increases the risk of bleeding in patients with impaired renal function.
    Pinkau T; Ndrepepa G; Kastrati A; Mann JF; Schulz S; Mehilli J; Schömig A
    Cardiology; 2008; 111(4):247-53. PubMed ID: 18434733
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Competing pharmacological strategies during PCI-analysis of a prematurely terminated trial.
    Kimmelstiel C
    Catheter Cardiovasc Interv; 2011 Jun; 77(7):1010-1. PubMed ID: 21598352
    [No Abstract]   [Full Text] [Related]  

  • 31. Prediction of 1-year clinical outcomes using the SYNTAX score in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a substudy of the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials.
    Garg S; Sarno G; Serruys PW; Rodriguez AE; Bolognese L; Anselmi M; De Cesare N; Colangelo S; Moreno R; Gambetti S; Monti M; Bristot L; Bressers M; Garcia-Garcia HM; Parrinello G; Campo G; Valgimigli M;
    JACC Cardiovasc Interv; 2011 Jan; 4(1):66-75. PubMed ID: 21251631
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardial infarction (ASSIST).
    Le May MR; Wells GA; Glover CA; So DY; Froeschl M; Marquis JF; O'Brien ER; Turek M; Thomas A; Kass M; Jadhav S; Labinaz M
    Circ Cardiovasc Interv; 2009 Aug; 2(4):330-8. PubMed ID: 20031736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stent thrombosis--a complication best avoided.
    Sharma M; Yeghiazarians Y
    J Invasive Cardiol; 2008 Apr; 20(4):166-7. PubMed ID: 18398231
    [No Abstract]   [Full Text] [Related]  

  • 34. Abciximab bolus with optional infusion in intervention for ST-elevation myocardial infarction.
    Berglund U; Nilsson L; Janzon M
    Scand Cardiovasc J; 2013 Aug; 47(4):230-5. PubMed ID: 23692139
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relation between clopidogrel discontinuation and early cardiovascular events after percutaneous coronary intervention with drug-eluting stents.
    Lemesle G; Torguson R; Bonello L; de Labriolle A; Maluenda G; Ben-Dor I; Collins SD; Syed AI; Xue Z; Satler LF; Pichard AD; Waksman R
    EuroIntervention; 2011 Apr; 6(9):1053-9. PubMed ID: 21518676
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty: a meta-analysis of 8 randomized trials.
    De Luca G; Verdoia M; Suryapranata H
    Atherosclerosis; 2012 Jun; 222(2):426-33. PubMed ID: 22483166
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized trial comparing clopidogrel versus ticlopidine therapy in patients undergoing infarct artery stenting for acute myocardial infarction with abciximab as adjunctive therapy.
    Parodi G; Sciagrà R; Migliorini A; Memisha G; Moschi G; Valenti R; Pupi A; Antoniucci D
    Am Heart J; 2005 Aug; 150(2):220. PubMed ID: 16086921
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study.
    Aleil B; Jacquemin L; De Poli F; Zaehringer M; Collet JP; Montalescot G; Cazenave JP; Dickele MC; Monassier JP; Gachet C
    JACC Cardiovasc Interv; 2008 Dec; 1(6):631-8. PubMed ID: 19463377
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The state of periprocedural antiplatelet therapy after recent trials.
    Desai NR; Bhatt DL
    JACC Cardiovasc Interv; 2010 Jun; 3(6):571-83. PubMed ID: 20630450
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents.
    Park DW; Yun SC; Lee SW; Kim YH; Lee CW; Hong MK; Cheong SS; Kim JJ; Park SW; Park SJ
    JACC Cardiovasc Interv; 2008 Oct; 1(5):494-503. PubMed ID: 19463351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.